secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001689375-23-000072
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics Q3 net income $35.5M; initiates Phase 1 for DMD candidate ENTR-601-44
--------------------------------------------------------------------------------

- Net income of $35.5M in Q3 2023 vs net loss of $(25.1M) in Q3 2022, driven by $43.7M collaboration revenue.
- Cash, cash equivalents and securities of $353.6M as of Sep 30, 2023; runway expected through 2025.
- Dosed first participant in Phase 1 trial of ENTR-601-44 for Duchenne muscular dystrophy; data expected H2 2024.
- Selected third Duchenne candidate ENTR-601-50 with IND/CTA planned for 2025; preclinical data expected H1 2024.
- Achieved Vertex milestone triggering $17.5M payment; entered license for ENTR-501 with Pierrepont Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000072/0001689375-23-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000072/trda-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001689375-23-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer